SAB Biotherapeutics Inc. (SABS)
NASDAQ: SABS
· Real-Time Price · USD
1.85
-0.03 (-1.44%)
At close: May 14, 2025, 11:37 AM
-1.44% (1D)
| Bid | 1.79 |
| Market Cap | 17.19M |
| Revenue (ttm) | 1.32M |
| Net Income (ttm) | -34.11M |
| EPS (ttm) | -3.68 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | -0.64 |
| Analyst | Buy |
| Ask | 1.99 |
| Volume | 36,513 |
| Avg. Volume (20D) | 45,381 |
| Open | 1.93 |
| Previous Close | 1.88 |
| Day's Range | 1.80 - 2.03 |
| 52-Week Range | 1.00 - 5.01 |
| Beta | 0.48 |
About SABS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SABS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SABS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
SAB Biotherapeutics Inc. is scheduled to release its earnings on May 27, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
8 months ago
+17.06%
SAB Biotherapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
9 months ago
-12.92%
SAB Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.
